These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 24051972)

  • 21. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis.
    Jumpsen JA; Brown NE; Thomson AB; Paul Man SF; Goh YK; Ma D; Clandinin MT
    J Cyst Fibros; 2006 May; 5(2):77-84. PubMed ID: 16507353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study.
    O'Connor MG; Thomsen K; Brown RF; Laposata M; Seegmiller A
    Prostaglandins Leukot Essent Fatty Acids; 2016 Oct; 113():46-49. PubMed ID: 27720040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients.
    Van Biervliet S; Devos M; Delhaye T; Van Biervliet JP; Robberecht E; Christophe A
    Prostaglandins Leukot Essent Fatty Acids; 2008 Feb; 78(2):109-15. PubMed ID: 18276127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study.
    Lloyd-Still JD; Powers CA; Hoffman DR; Boyd-Trull K; Lester LA; Benisek DC; Arterburn LM
    Nutrition; 2006 Jan; 22(1):36-46. PubMed ID: 16226012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis.
    Olveira G; Olveira C; Acosta E; Espíldora F; Garrido-Sánchez L; García-Escobar E; Rojo-Martínez G; Gonzalo M; Soriguer F
    Arch Bronconeumol; 2010 Feb; 46(2):70-7. PubMed ID: 20045240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis.
    Al-Turkmani MR; Freedman SD; Laposata M
    Prostaglandins Leukot Essent Fatty Acids; 2007; 77(5-6):309-18. PubMed ID: 18036797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis.
    Coste TC; Armand M; Lebacq J; Lebecque P; Wallemacq P; Leal T
    Clin Biochem; 2007 May; 40(8):511-20. PubMed ID: 17316592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease.
    Sijben JW; Calder PC
    Proc Nutr Soc; 2007 May; 66(2):237-59. PubMed ID: 17466105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Essential fatty acid supplementation of DHA and ARA and effects on neurodevelopment across animal species: a review of the literature.
    Davis-Bruno K; Tassinari MS
    Birth Defects Res B Dev Reprod Toxicol; 2011 Jun; 92(3):240-50. PubMed ID: 21678548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prenatal long-chain polyunsaturated fatty acid status: the importance of a balanced intake of docosahexaenoic acid and arachidonic acid.
    Hadders-Algra M
    J Perinat Med; 2008; 36(2):101-9. PubMed ID: 18211254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty acids in cystic fibrosis.
    Freedman SD; Shea JC; Blanco PG; Alvarez JG
    Curr Opin Pulm Med; 2000 Nov; 6(6):530-2. PubMed ID: 11100964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioactive Food Components as Dietary Intervention for Cystic Fibrosis.
    Sirinupong N; Yang Z
    Curr Drug Targets; 2015; 16(9):988-92. PubMed ID: 25418859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical effects of diet supplementation with DHA in pediatric patients suffering from cystic fibrosis.
    Leggieri E; De Biase RV; Savi D; Zullo S; Halili I; Quattrucci S
    Minerva Pediatr; 2013 Aug; 65(4):389-98. PubMed ID: 24051972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
    Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B
    Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.